BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension
| Status: | Active, not recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), High Blood Pressure (Hypertension) |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/6/2019 |
| Start Date: | March 12, 2009 |
| End Date: | November 29, 2019 |
Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934)
will be asked to participate in this long term extension study with BAY63-2521.
will be asked to participate in this long term extension study with BAY63-2521.
Inclusion Criteria:
- Patients who have completed 12 weeks of treatment in the double blind trial PATENT 1
Exclusion Criteria:
- Patients who have an ongoing serious adverse event from PATENT 1 that is assessed as
related to BAY63-2521 are not allowed to participate in the extension trial.
We found this trial at
11
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials